TNF and uveitis: Adalimumab, an FDA-approved anti-TNF agent for uveitis, is a fully humanized IgG1 monoclonal antibody that neutralizes tumor necrosis factor (TNF)-alpha activity and induces apoptosis of TNF-expressing cells [18].